NKGen Biotech Inc (NASDAQ: NKGN)’s stock price has gone rise by 12.73 in comparison to its previous close of 0.26, however, the company has experienced a 10.59% increase in its stock price over the last five trading days. globenewswire.com reported 2024-10-29 that Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15, and LTBP2 levels, which are detectable up to 10 years before dementia symptoms appear according to recent reports. This suggests a potential role for the use of troculeucel in delaying or preventing dementia onset in asymptomatic individuals with detectable biomarkers.
Is It Worth Investing in NKGen Biotech Inc (NASDAQ: NKGN) Right Now?
Company’s 36-month beta value is 0.52.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NKGN is 18.20M, and currently, short sellers hold a 3.92% ratio of that floaft. The average trading volume of NKGN on November 19, 2024 was 1.13M shares.
NKGN’s Market Performance
The stock of NKGen Biotech Inc (NKGN) has seen a 10.59% increase in the past week, with a -25.59% drop in the past month, and a -63.72% fall in the past quarter. The volatility ratio for the week is 14.31%, and the volatility levels for the past 30 days are at 15.68% for NKGN. The simple moving average for the past 20 days is -1.08% for NKGN’s stock, with a -72.54% simple moving average for the past 200 days.
NKGN Trading at -23.67% from the 50-Day Moving Average
After a stumble in the market that brought NKGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.67% of loss for the given period.
Volatility was left at 15.68%, however, over the last 30 days, the volatility rate increased by 14.31%, as shares sank -34.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.23% lower at present.
During the last 5 trading sessions, NKGN rose by +10.59%, which changed the moving average for the period of 200-days by -81.75% in comparison to the 20-day moving average, which settled at $0.3007. In addition, NKGen Biotech Inc saw -89.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKGN starting from Song Paul Y., who purchase 76 shares at the price of $3.29 back on Dec 07 ’23. After this action, Song Paul Y. now owns 171,121 shares of NKGen Biotech Inc, valued at $250 using the latest closing price.
Song Paul Y., the Chief Executive Officer of NKGen Biotech Inc, purchase 75 shares at $3.32 during a trade that took place back on Dec 06 ’23, which means that Song Paul Y. is holding 171,045 shares at $250 based on the most recent closing price.
Stock Fundamentals for NKGN
The total capital return value is set at 0.88. Equity return is now at value -118.66, with -196.21 for asset returns.
Based on NKGen Biotech Inc (NKGN), the company’s capital structure generated -0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -1.12. The debt to equity ratio resting at -0.4. The interest coverage ratio of the stock is -13.28.
Currently, EBITDA for the company is -28.54 million with net debt to EBITDA at -0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.02.
Conclusion
In a nutshell, NKGen Biotech Inc (NKGN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
